Estrogen Receptor Agonist Market Trends

Growth Drivers

Growing Prevalence of Osteoporosis 18.3% of people worldwide were estimated to have osteoporosis in 2021. Hence, in order to treat osteoporosis, the demand is on a surge for estrogen receptor agonists. Raloxifene is the most common type of estrogen which is approved by FDA used for this treatment.
Rise in Women Suffering from PCOS Between 4% and 20% of women worldwide were believed to have PCOS in 2022. Further, PCOS have a huge adverse effect on female leading to irregular period and acne. Hence, polycystic ovary syndrome treatment on timely basis is necessary. Therefore, in order to control menstrual cycles in PCOS patients, oral contraceptives (OCs; with combined estrogen and progestin) are the most widely used form of medication.
Surge in the Application of Estrogen in Asthma There has been growing research on the use of estrogen receptor agonist in the treatment of asthma. Beyond the reproductive system, estrogen plays a variety of tasks in both males and females, including controlling inflammation, intracellular calcium levels, and cell proliferation and differentiation. One of the characteristics of asthma is the infiltration of inflammatory cells such as lymphocytes, monocytes/macrophages, neutrophils, and eosinophils into the airways, particularly eosinophilic infiltration. Hence, it is poised that the estrogen receptor agonist would be used. Hence, further, the investment in research activities on this topic is anticipated to rise in order to prove the conclusion.

Challenges

High Cost of Treatment
Lack of Processionals who are Skilled in this Field – The use of estrogen receptor agonists is a new form of treatment on which still research is going on for its use to treat different diseases. Hence, not a large number of people are aware of this treatment. Also, since it is not popular enough there is a lack of professionals, especially in rural regions. Hence, this factor is projected to hinder the estrogen receptor agonist market growth.
Adverse Effect of Estrogen Receptor Agonist

Estrogen Receptor Agonist Market: Key Insights

Base Year	2022
Forecast Year	2023-2035
CAGR	~ 7%
Base Year Market Size (2022)	~ USD 4 Billion
Forecast Year Market Size (2035)	~ USD 9 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are the growing prevalence of osteoporosis, the rise in women suffering from PCOS, and the surge in the application of estrogen in asthma.

The market size of estrogen receptor agonist is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2035.

The major players in the market are AstraZeneca, Eli Lilly and Company, ESTRIGENIX, Karo Healthcare AB, and more.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product type, indication type, route of administration, distribution channel and by region.

The oral segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

High cost of treatment, lack of professions who are skilled in this field, and adverse effect of estrogen receptor agonist are estimated to be the growth hindering factors for the market expansion.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

Estrogen Receptor Agonist Market Trends